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Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastroin-
testinal tract, representing 1e3% of gastrointestinal malignancies. The majority of GISTs present at age
50e70 years. Pediatric GISTs are considered to be biologically distinct from adult GISTs. The incidence of
malignant GISTs is less in children than in adults. Signiﬁcant clinical and genetic differences are also
noted between the two. A pediatric case typically affects females; is multifocal; is sited more commonly
in the stomach and follows an indolent course. Histologically, epithelioid morphology is common and
genetically most tumors lack mutations in the KIT or PDGFRA genes. We report a 12 year old male child
presenting with a highly vascular stomach GIST for whom we did a pylorus-preserving wide local
excision. On histopathology it was a malignant variety of GIST of epithelioid type; positive for c-KIT &
CD34. The boy is now on Imatinib Mesylate chemotherapy and is asymptomatic.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Gastrointestinal stromal tumors (GISTs) are nonepithelial
tumors of connective tissue of the gastrointestinal tract. About
60% occur in the stomach, 30% in the small intestine and less
than 1% in the esophagus. Very rarely do they occur in other
abdominal organs. Smaller tumors are usually benign, especially
when cell division rate is slow, but large tumors tend to
disseminate to the liver, omentum and peritoneal cavity. The
incidence of GISTs is estimated to be approximately 10e20 per
million people per year, of which 20e30% are malignant. Over
90% of GISTs occur in adults over 40 years, with a median age
of 63 years [1e3]. GISTs occurring in the pediatric age group
are extremely rare and form a distinct clinical and molecular
subset from the adult tumors (Table 1). Almost all GISTs diag-
nosed in children occur in girls, have multifocal gastric location
and lack oncogenic mutations in KIT or PDGFRA genes [1e3].
Infrequently, boys are affected; and in this setting their tumors
usually do not resemble the typical pediatric GISTs phenotype,
showing variability in extra-gastric location and/or KIT/PDGFRA
mutations [1e3]. We report a rare case of a c-KIT positiveile).
relkar).
Inc. Open access under CC BY-NC-NDmalignant GIST of epithelioid variety occurring in a 12 year old
male child.1. Case report
A 12-year old boy presented to uswith complaints of dull-aching
continuous epigastric pain, nausea and generalized weakness for
six months. He had signiﬁcant weight loss (4 kg in one month) and
also had a single episode of melena 3 months before. He had sig-
niﬁcant pallor and a soft abdomen with no palpable lump. Per-
rectal examination was normal. Ultrasound of the abdomen
showed a 6 cm  6.5 cm heterogenous mass in the lesser sac
continuous with the stomach but free from surrounding structures.
Contrast enhanced computerized tomography (CECT) showed
extensive breakdown within the mass which was continuous with
stomach but free from surrounding structures, without lymph-
adenopathy or liver metastases (Fig. 1). An ultrasound guided bi-
opsy showed only ﬁbrocollagenous tissue with inﬂammatory cells.
Blood transfusion was given to correct anemia and the child was
explored through a vertical midline incision. We found a large
8 8 cm vascular and friable mass arising from the lesser curvature
of the stomach with well deﬁned margins. As the mass was very
vascular and friable, and USG guided biopsy was inconclusive for
malignancy, only an incisional biopsy was taken. Histopathology
showed epithelioid cells highly suggestive of GIST with rare license.
Table 1
Typical differences between adult and pediatric GIST.
Adults Pediatrics
Males > female Females > males
Can start anywhere in the GI tract Usually starts in the stomach
Starts at a single tumor site May present with multiple stomach
tumors (“multifocal” or
“multinodular”)
Rarely metastasizes to the lymph
nodes
Lymph node metastases are more
common
Faster growing Slower growing
Tumor cells usually have a spindle
shape
Tumor cells usually have an
epitheloid shape
Has a high response rate to the current
ﬁrst-line drug treatment, Imatinib
Mesylate
Has an undeﬁned; but generally
lower response rate to Imatinib
Mesylate
Typically has mutations in either KIT
or PDGFRA genes
Typically does not have KIT or
PDGFRA mutations
Fig. 2. Intraoperative picture with tumor.
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explored after 8 days, once the deﬁnitive diagnosis of GIST was
made, and wedge resection of the tumor was done along the lesser
curvature with 2 cm normal margin, saving the pylorus (Figs. 2e4).
Postoperative course was uneventful. Final histopathology report of
the mass proved it to be GIST of high malignant potential. On
immunohistochemistry, the tumor was positive for CD34 & c-KIT
but negative for DOG-1, EMA and CK. He was started on Imatinib
Mesylate chemotherapy (200 mg twice daily) and is continuing the
same without any side effects. Follow up after 1.5 year shows no
evidence of recurrence on computed tomography scan (Fig. 5) (not
mandatory). Child is growing well, has continued his education.2. Discussion
GISTs are rare tumors arising from interstitial cells of Cajal,
which are normally part of the autonomic nervous system of the
intestine. They serve a pacemaker function in controlling motility.
The diagnosis of GISTs might have often been missed in the past. A
more stringent deﬁnition of the disease and the introduction of a
speciﬁc molecular targeted therapy drew attention to it and its
differential diagnosis. Thus, the annual incidence which earlier was
thought to be 0.5/100,000, is now almost 1.5/100,000 new cases per
year [4]. These tumors were initially thought to belong to theFig. 1. Picture of preoperative computerized tomography scan.smooth muscle cell family [5]. Later on, cases with nerve sheath
differentiation were described (gastrointestinal autonomic nerve
tumors, or GANT, now considered a variant of GISTs), along with
cases lacking characteristics of either [6,7]. A relationship to the
interstitial cells of Cajal has now been established on the basis of
some common phenotypical features of GISTs [4]. The differential
diagnosis is conventional leiomyosarcomas; however both have
different natural history and drug sensitivity [8,9]. Physiologically,
the system of interstitial cells of Cajal is involved in the control of
gut motility. In fact, interstitial cells of Cajal are known as the
gastrointestinal pacemaker cells, hence the alternative termGIPACT
(gastrointestinal pacemaker cell tumors) has been proposed for
GISTs.
There are important differences between pediatric GISTs and
adult GISTs (Table 1). Pediatric GISTs can be further divided into
subgroups. The most familiar and commonest type is simply called
“Pediatric GISTs.” It most commonly affects girls aged 6e18 years
and almost always starts in the stomach. However, it can occur after
the age of 18 years [10e12]. The secondwell-known type of GISTs in
children is called “Carney’s Triad” named after Dr. J. Aidan Carney
who ﬁrst described it in 1977. Patients with Carney’s triad mustFig. 3. Intraoperative picture post excision of tumor.
Fig. 4. Picture of specimen.
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chondroma, and/or functioning extra-adrenal paraganglioma,
particularly if age and sex factors are supportive [10e12].
Two additional subtypes of pediatric GIST which are even rarer;
Carney-Stratakis Syndrome (familial paraganglioma and gastric
stromal sarcoma) which is familial, and “Neonatal GIST” which
occurs in newborns.
Emerging evidence suggests that the various forms of pediatric
GISTs are related by deﬁciencies of a protein called succinate de-
hydrogenase [10e12]. All female patients and about two-thirds of
male patients lack activating mutations in KIT/PDGFRA [13,14].
Morphologically the tumors have either a predominantly epithe-
lioid or mixed epithelioid e spindle cell appearance [13,14].
Pediatric GISTs have indolent clinical behavior, even in the
presence of loco-regional or distant metastatic disease. Long termFig. 5. Picture of computerized tomography scan at 1 year follow up.follow-up of these patients in the pre-Imatinib era showed a pro-
longed survival with slow growth and tumor progression even in
the absence of targeted kinase inhibition. These ﬁndings suggest
distinct tumor biology of GISTs affecting children, with possibly
alternative molecular mechanisms and signaling pathways down-
stream of the KIT receptor.
The clinical ﬁndings vary depending on the location and size of
the tumor at presentation. If the tumor is small, it may be only an
incidental ﬁnding during radiological imaging or surgery for some
other cause, whereas a large exophytic lesion may present as an
abdominal mass due to its large size. Lesions in the stomach, small
bowel, or colon may present with gastrointestinal bleed in the form
of hematemesis, melena, or occult blood in stools; alternatively,
there may be abdominal pain, nausea, and vomiting. An esophageal
GIST most commonly presents with dysphagia [15].
As is evident from the case being reported, a pediatric gastric
GIST can pose a diagnostic dilemma even after an USG guided bi-
opsy and should be considered a differential diagnosis in lesser sac
tumors despite atypical presentation and in cases of inconclusive
biopsies.
GISTs can occur anywhere along the GI tract, but most often are
found in the stomach or small intestine. The American Joint Com-
mittee on Cancer (AJCC) Staging Manual lists the distributions in
this order; stomach (60%), small intestine (30%), rectum (3%), colon
(1e2%), esophagus (<1%), omentum/mesentery (rare) [16]. A single
case has been reported of GISTs occurring in appendix [17].
Because most of these tumors in pediatric as well as adult pa-
tients are submucosal in location, they usually attain a large size
without causing bowel obstruction by the time of diagnosis [18].
Many of these tumors have an exophytic component as they arise
from the muscularis propria (Marla et al. [19]). Lee et al. [20,21]
found GIST to be well-deﬁned tumors with homogenous
enhancement, while Levy et al. found large heterogeneously
enhancing masses due to areas of necrosis or cystic degeneration.
They described ulceration as a common feature of GISTs.
Metastases from GISTs in pediatric as well as adult patients
commonly occur to the liver and peritoneal cavity and occasionally
soft tissues, lungs, and pleura. Marla et al. also found that tumors
that enhanced homogenously (nine out of 53 cases in their series)
showed no metastases when they were followed for a mean period
of 2.6 years as compared with those that enhanced heteroge-
neously. According to Nilsson et al. [22], at least 50% of these tumors
have metastasis at presentation.
Surgery is the deﬁnitive therapy for patients with GISTs. Radical
and complete surgical extirpation offers the only chance for cure.
For localized primary GISTs, surgical resection is the mainstay of
therapy with the 5-year survival rate after complete resection
averaging approximately 50e65%. Surgery is also indicated in
symptomatic patients with locally advanced or metastatic disease.
Debulking large lesions is helpful when adjuvant therapy with
Imatinib Mesylate is contemplated.
Preoperative Imatinib should be considered if surgical morbidity
would be improved by cytoreducing the size of the tumor.
Postoperative Imatinib has been shown to increase recurrence-
free survival after complete resection of localized GISTs. In 2012,
Joensuu et al. showed that 36 months of Imatinib improved
recurrence free survival and overall survival of GISTs patients with a
high risk of GIST recurrence, compared with 12 months of adjuvant
Imatinib.
The optimal follow-up schedules are not known. High-risk pa-
tients undergo a routine follow-up with CT scan or MRI every 3e6
months for 3 years during adjuvant therapy (with tighter clinical
follow-up due to the need to manage the side effects of adjuvant
therapy), unless contraindicated, then on cessation of adjuvant
therapy every 3 months for 2 years, then every 6 months until 5
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tional 5 years. For low-risk tumors, the usefulness of a routine
follow-up is not known; if selected, this is carried out with a CT scan
orMRI every 6e12months for 5 years. Very low-risk GISTs probably
do not deserve routine follow-up, although one must be aware that
the risk is not nil. X-ray exposure is a factor to take into account,
with abdominal MRI being an option as an alternative option to a CT
scan [23].
Factors such as tumor size, mitotic rate, tumor location, kinase
mutational status and occurrence of tumor rupture have been
proposed as predictors of outcome. Adjuvant Imatinib is proposed
as an option for those patients with a substantial risk of relapse.
Unresectable metastatic or recurrent GISTs can be treated with
Imatinib, with a remarkable response rate (50e70%) and prolonged
survival (median progression-free survival: 18e20 months; median
overall survival: 51e57 months). Sunitinib is licensed as a second-
line therapy following progression on Imatinib. Other promising
systemic therapies include Regorafenib and agents targeting the
PI3K/mTOR pathway [24].3. Conclusion
Gastrointestinal stromal tumors are very rare in pediatric age
group more so in males, when they are usually c-KIT negative and
have doubtful response to Imatinib. However as is evident in the
indexed case, boys may be c-KIT positive and have a better prog-
nosis and good response to Imatinib.References
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